Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease
Diabetes/Metabolism Research and Reviews · 2025-09 · 41 (6)
DOI: 10.1002/dmrr.70086 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes/Metabolism Research and Reviews, online erschienen am 07.09.2025. Verfasst von Feng Liang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Endothelium, Vascular. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 158 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Chronic kidney disease (CKD) substantially increases cardiovascular risk, with endothelial dysfunction as its central pathological mechanism. This review summarises the molecular regulatory mechanisms underlying endothelial dysfunction in CKD and highlights recent advances in treatment strategies. The pathophysiology of endothelial injuries involves a complex network of multiple factors and mechanisms, including oxidative stress, inflammation, glycocalyx damage, ischaemia, hypoxia, cellular senescence and endothelial‐mesenchymal transition (EndMT). Recent advances have yielded several promising CKD treatment strategies, including dual endothelin‐angiotensin receptor antagonists (DEARA), dipeptidyl peptidase‐4 inhibitors (DPP‐4i), glucagon‐like peptide‐1 receptor agonists (GLP‐1RA), renin‐angiotensin‐aldosterone system inhibitors (RAASi), sodium‐glucose cotransporter 2 inhibitors (SGLT2i) and mineralocorticoid receptor antagonists (MRA), which have demonstrated favourable protective effects on endothelial cells. Moreover, emerging anti‐ageing therapies are novel therapeutic directions for research related to endothelial protection. In future studies, the synergistic effects of nonpharmacological interventions (such as lifestyle modifications and nutritional support) and pharmacological therapies will be a new direction, providing ideas for improving endothelial dysfunction, decelerating the progression of CKD, reducing the risk of cardiovascular events, and ultimately improving patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Daping Hospital, Army Medical University, Chongqing, China.
- The Key Laboratory of Precision Diagnosis and Treatment for Kidney Diseases of Chongqing, Chongqing, China.
- State Key Laboratory of Trauma, Burn and Combined Injury, Army Medical University, Chongqing, China.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liang, F., Li, G., Chen, K., Chen, J., He, J., & He, Y. (2025). Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease. Diabetes/Metabolism Research and Reviews, 41(6). https://doi.org/10.1002/dmrr.70086
Vancouver
Liang F, Li G, Chen K, Chen J, He J, He Y. Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease. Diabetes/Metabolism Research and Reviews. 2025;41(6). doi:10.1002/dmrr.70086
BibTeX
@article{Liang2025,
author = {Liang, Feng and Li, Gui and Chen, Kehong and Chen, Jia and He, Junling and He, Yani},
title = {Endothelial Dysfunction and Therapeutic Advances in Chronic Kidney Disease},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2025},
volume = {41},
number = {6},
doi = {10.1002/dmrr.70086}
}
EUVIMED